Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma-Reference-Cited by-同舟云学术

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Published:2017-01 Issue:1 Volume:25 Page:285-295
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Locke Frederick L.,Neelapu Sattva S.,Bartlett Nancy L.,Siddiqi Tanya,Chavez Julio C.,Hosing Chitra M.,Ghobadi Armin,Budde Lihua E.,Bot Adrian,Rossi John M.,Jiang Yizhou,Xue Allen X.,Elias Meg,Aycock Jeff,Wiezorek Jeff,Go William Y.

Funder

Kite Pharma

Leukemia & Lymphoma Society Therapy Acceleration Program

Moffitt Cancer Center

MD Anderson Cancer Center

National Cancer Institute

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference32 articles.

1. Guidelines for the management of diffuse large B-cell lymphoma;Chaganti;Br. J. Haematol.,2016

2. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

3. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

4. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12;Crump;J. Clin. Oncol.,2014

5. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma;Matasar;Blood,2013

Cited by 517 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin’s Lymphoma;Clinical Pharmacokinetics;2024-09-06

2. Acute kidney injury following chimeric antigen receptor T-cell therapy: Epidemiology, mechanism and prognosis;Clinical Immunology;2024-09

3. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

4. The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis;European Journal of Haematology;2024-08-22

5. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22